scholarly journals Clinical Development of Novel Drug–Radiotherapy Combinations

2018 ◽  
Vol 25 (5) ◽  
pp. 1455-1461 ◽  
Author(s):  
Saif S. Ahmad ◽  
Marka R. Crittenden ◽  
Phuoc T. Tran ◽  
Paul G. Kluetz ◽  
Gideon M. Blumenthal ◽  
...  
Keyword(s):  
Clinical Development ◽  
Novel Drug

Novel drug targets in clinical development for heart failure

2014 ◽  
Vol 70 (7) ◽  
pp. 765-774 ◽  
Author(s):  
Melvin George ◽  
Muthukumar Rajaram ◽  
Elangovan Shanmugam ◽  
Thangavel Mahalingam VijayaKumar
Keyword(s):  
Heart Failure ◽  
Drug Targets ◽  
Clinical Development ◽  
Novel Drug ◽  
Novel Drug Targets

scholarly journals Recent advances in the understanding and treatment of acute myeloid leukemia

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1196 ◽  
Author(s):  
Justin Watts ◽  
Stephen Nimer
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Drug Targets ◽  
Poor Prognosis ◽  
Clinical Development ◽  
New Drugs ◽  
Recent Advances ◽  
Novel Drug ◽  
Novel Drug Targets ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

scholarly journals The future of combination therapies in advanced melanoma

2020 ◽  
Vol 13 (3) ◽  
pp. 309-313 ◽  
Author(s):  
Christoph Hoeller
Keyword(s):  
Clinical Trials ◽  
Targeted Therapy ◽  
Clinical Development ◽  
Advanced Melanoma ◽  
Drug Combinations ◽  
Combination Therapies ◽  
Combination Strategies ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Novel Drug

Summary The combination of Cytotoxic T-Lymphozyte Antigen-4 (CTLA‑4) and Programmed death-1 (PD‑1) antibodies and the combination of BRAF and MEK inhibitors are the current clinical standards for combination immune and targeted therapy for melanoma, respectively. The success of these therapies has stimulated research into novel drug combinations for melanoma, of which a large majority are based on combination with PD‑1 or PD-Ligand 1 (PD-L1) blocking drugs. Thus, the aim is to provide an overview of the most important combination strategies in late stage clinical development and an outlook on drug combinations in early development that might enter larger clinical trials within the next few years.

COVID-19 must catalyse changes to clinical development

2020 ◽  
Vol 19 (10) ◽  
pp. 653-654
Author(s):  
Rod MacKenzie ◽  
Peter Honig ◽  
Judy Sewards ◽  
Robert Goodwin ◽  
Marie-Pierre Hellio
Keyword(s):  
Clinical Development
Sign in / Sign up

Export Citation Format

Share Document